Inno­gen nets $120M to ad­vance Trulic­i­ty, Ozem­pic ri­val; ven­ture in­to man­u­fac­tur­ing

A low pro­file, Chi­nese biotech has been work­ing on de­vel­op­ing drugs for di­a­betes and meta­bol­ic dis­or­ders. Now, the com­pa­ny, known as Inno­gen Phar­ma­ceu­ti­cal Tech­nol­o­gy, has nabbed $120 mil­lion in ven­ture cap­i­tal.

Deal Street Asia re­port­ed on the fi­nanc­ing this morn­ing, list­ing the lead in­vestors as Youshan Cap­i­tal and Chi­na Growth Cap­i­tal. Oth­er in­vestors in­clude CI­CC Qide Fund, V Star Cap­i­tal and Chi­na Ever­bright Lim­it­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER